Dennis Purcell

Dennis Joseph Purcell is the founder of Aisling Capital LLC, founded in 1998, serving as Senior Advisor since its founding.
Current jobs include Non-Executive Chairman at Solvonis Therapeutics Plc since 2024; Director at Rosetta Capital Ltd. since 2017; Director at Real Endpoints LLC; Independent Director and Advisor at Bioscience Managers Pty Ltd. since 2003; Chief Operating Officer & Director at Summus Global, Inc.; Non-Executive Director at Ichnos Glenmark Innovation, Inc.; Director at ViralClear Pharmaceuticals, Inc. since 2020; and Advisor at The New York City Investment Fund Manager, Inc. Former jobs include Special Advisor to the CEO at Awakn Life Sciences Corp.; Executive Chairman at Poliwogg Holdings, Inc.; Director at Valentis, Inc.; Director at Paratek Pharmaceuticals, Inc. from 2009 to 2012; Director at Cengent Therapeutics, Inc.; Director at Bridge Pharmaceuticals, Inc.; Director at Biotechnology Innovation Organization; Director at Embera NeuroTherapeutics, Inc.; Director at Dynova Laboratories, Inc.; Managing Director at PaineWebber, Inc.; Director at Aton Pharma, Inc.; Managing Director at Chase H&Q from 1995 to 1998; Director at Xanodyne Pharmaceuticals, Inc.; Director at New York Biotechnology Association, Inc.; Director at The Irvington Institute for Immunological Research; and Member at Harvard Medical School.
Education includes an MBA from Harvard University and undergraduate studies at the University of Delaware.